vs
Alight, Inc.（ALIT）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Alight, Inc.的季度营收约是Royalty Pharma plc的1.0倍（$653.0M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs -142.7%，领先177.2%），Royalty Pharma plc同比增速更快（4.8% vs -4.0%），过去两年Alight, Inc.的营收复合增速更高（8.1% vs 4.6%）
Alight公司是一家美国信息技术与咨询企业，专注于人力资源相关业务，主打基于云的系统服务、业务外包与咨询服务，为大型企业提供人力资本管理平台与外包方案，业务范围涵盖健康福利管理、财务管理以及退休规划等领域。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ALIT vs RPRX — 直观对比
营收规模更大
ALIT
是对方的1.0倍
$622.0M
营收增速更快
RPRX
高出8.7%
-4.0%
净利率更高
RPRX
高出177.2%
-142.7%
两年增速更快
ALIT
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $653.0M | $622.0M |
| 净利润 | $-932.0M | $214.2M |
| 毛利率 | 36.8% | — |
| 营业利润率 | -114.9% | 62.4% |
| 净利率 | -142.7% | 34.4% |
| 营收同比 | -4.0% | 4.8% |
| 净利润同比 | -11750.0% | 2.9% |
| 每股收益（稀释后） | $-1.77 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALITRPRX
| Q4 25 | $653.0M | $622.0M | ||
| Q3 25 | $533.0M | $609.3M | ||
| Q2 25 | $528.0M | $578.7M | ||
| Q1 25 | $548.0M | $568.2M | ||
| Q4 24 | $680.0M | $593.6M | ||
| Q3 24 | $555.0M | $564.7M | ||
| Q2 24 | $538.0M | $537.3M | ||
| Q1 24 | $559.0M | $568.0M |
净利润ALITRPRX
| Q4 25 | $-932.0M | $214.2M | ||
| Q3 25 | $-1.1B | $288.2M | ||
| Q2 25 | $-1.1B | $30.2M | ||
| Q1 25 | $-25.0M | $238.3M | ||
| Q4 24 | $8.0M | $208.2M | ||
| Q3 24 | $-74.0M | $544.0M | ||
| Q2 24 | $23.0M | $102.0M | ||
| Q1 24 | $-114.0M | $4.8M |
毛利率ALITRPRX
| Q4 25 | 36.8% | — | ||
| Q3 25 | 33.4% | — | ||
| Q2 25 | 33.3% | — | ||
| Q1 25 | 31.2% | — | ||
| Q4 24 | 39.9% | — | ||
| Q3 24 | 31.4% | — | ||
| Q2 24 | 31.0% | — | ||
| Q1 24 | 32.6% | — |
营业利润率ALITRPRX
| Q4 25 | -114.9% | 62.4% | ||
| Q3 25 | -248.0% | 70.1% | ||
| Q2 25 | -191.3% | 36.3% | ||
| Q1 25 | -1.5% | 94.0% | ||
| Q4 24 | 6.5% | 60.9% | ||
| Q3 24 | -7.6% | — | ||
| Q2 24 | -9.7% | 50.2% | ||
| Q1 24 | -7.2% | -13.0% |
净利率ALITRPRX
| Q4 25 | -142.7% | 34.4% | ||
| Q3 25 | -200.2% | 47.3% | ||
| Q2 25 | -203.2% | 5.2% | ||
| Q1 25 | -4.6% | 41.9% | ||
| Q4 24 | 1.2% | 35.1% | ||
| Q3 24 | -13.3% | 96.3% | ||
| Q2 24 | 4.3% | 19.0% | ||
| Q1 24 | -20.4% | 0.8% |
每股收益（稀释后）ALITRPRX
| Q4 25 | $-1.77 | $0.49 | ||
| Q3 25 | $-2.02 | $0.67 | ||
| Q2 25 | $-2.03 | $0.07 | ||
| Q1 25 | $-0.05 | $0.55 | ||
| Q4 24 | $0.02 | $0.46 | ||
| Q3 24 | $-0.14 | $1.21 | ||
| Q2 24 | $0.04 | $0.23 | ||
| Q1 24 | $-0.21 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $273.0M | $618.7M |
| 总债务越低越好 | $2.0B | $9.0B |
| 股东权益账面价值 | $1.0B | $9.7B |
| 总资产 | $4.6B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.92× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ALITRPRX
| Q4 25 | $273.0M | $618.7M | ||
| Q3 25 | $205.0M | $938.9M | ||
| Q2 25 | $227.0M | $631.9M | ||
| Q1 25 | $223.0M | $1.1B | ||
| Q4 24 | $343.0M | $929.0M | ||
| Q3 24 | $300.0M | $950.1M | ||
| Q2 24 | $183.0M | $1.8B | ||
| Q1 24 | $256.0M | $843.0M |
总债务ALITRPRX
| Q4 25 | $2.0B | $9.0B | ||
| Q3 25 | $2.0B | $8.9B | ||
| Q2 25 | $2.0B | $8.0B | ||
| Q1 25 | $2.0B | $7.6B | ||
| Q4 24 | $2.0B | $7.6B | ||
| Q3 24 | $2.0B | $7.6B | ||
| Q2 24 | $2.8B | $7.6B | ||
| Q1 24 | $2.8B | $6.1B |
股东权益ALITRPRX
| Q4 25 | $1.0B | $9.7B | ||
| Q3 25 | $2.0B | $9.6B | ||
| Q2 25 | $3.1B | $9.5B | ||
| Q1 25 | $4.2B | $9.8B | ||
| Q4 24 | $4.3B | $10.3B | ||
| Q3 24 | $4.3B | $10.3B | ||
| Q2 24 | $4.5B | $9.8B | ||
| Q1 24 | $4.5B | $9.9B |
总资产ALITRPRX
| Q4 25 | $4.6B | $19.6B | ||
| Q3 25 | $5.5B | $19.3B | ||
| Q2 25 | $6.8B | $18.3B | ||
| Q1 25 | $7.9B | $17.6B | ||
| Q4 24 | $8.2B | $18.2B | ||
| Q3 24 | $8.3B | $18.0B | ||
| Q2 24 | $10.5B | $17.7B | ||
| Q1 24 | $10.7B | $16.1B |
负债/权益比ALITRPRX
| Q4 25 | 1.92× | 0.92× | ||
| Q3 25 | 1.00× | 0.93× | ||
| Q2 25 | 0.65× | 0.84× | ||
| Q1 25 | 0.48× | 0.78× | ||
| Q4 24 | 0.47× | 0.74× | ||
| Q3 24 | 0.47× | 0.74× | ||
| Q2 24 | 0.62× | 0.78× | ||
| Q1 24 | 0.62× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $124.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $99.0M | — |
| 自由现金流率自由现金流/营收 | 15.2% | — |
| 资本支出强度资本支出/营收 | 3.8% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $250.0M | — |
8季度趋势，按日历期对齐
经营现金流ALITRPRX
| Q4 25 | $124.0M | $827.1M | ||
| Q3 25 | $77.0M | $702.6M | ||
| Q2 25 | $86.0M | $364.0M | ||
| Q1 25 | $73.0M | $596.1M | ||
| Q4 24 | $118.0M | $742.5M | ||
| Q3 24 | $-24.0M | $703.6M | ||
| Q2 24 | $58.0M | $658.2M | ||
| Q1 24 | $100.0M | $664.6M |
自由现金流ALITRPRX
| Q4 25 | $99.0M | — | ||
| Q3 25 | $49.0M | — | ||
| Q2 25 | $58.0M | — | ||
| Q1 25 | $44.0M | — | ||
| Q4 24 | $92.0M | — | ||
| Q3 24 | $-52.0M | — | ||
| Q2 24 | $22.0M | — | ||
| Q1 24 | $69.0M | — |
自由现金流率ALITRPRX
| Q4 25 | 15.2% | — | ||
| Q3 25 | 9.2% | — | ||
| Q2 25 | 11.0% | — | ||
| Q1 25 | 8.0% | — | ||
| Q4 24 | 13.5% | — | ||
| Q3 24 | -9.4% | — | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | 12.3% | — |
资本支出强度ALITRPRX
| Q4 25 | 3.8% | — | ||
| Q3 25 | 5.3% | — | ||
| Q2 25 | 5.3% | — | ||
| Q1 25 | 5.3% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 5.0% | — | ||
| Q2 24 | 6.7% | — | ||
| Q1 24 | 5.5% | — |
现金转化率ALITRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | 14.75× | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | 2.52× | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALIT
| Recurring | $607.0M | 93% |
| Projects | $46.0M | 7% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
